News articles about Corindus Vascular Robotics (NYSE:CVRS) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Corindus Vascular Robotics earned a news impact score of 0.16 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.9165321572304 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Corindus Vascular Robotics (NYSE CVRS) opened at 1.90 on Friday. Corindus Vascular Robotics has a 1-year low of $0.40 and a 1-year high of $2.25. The company’s market cap is $355.86 million. The stock’s 50 day moving average price is $1.70 and its 200 day moving average price is $1.39.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Corindus Vascular Robotics (CVRS) Share Price” was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.